Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing to sign a consent form and agree to follow the study schedule, including long-term check-ins for up to 15 years
- You are between 18 and 75 years old
- You have been diagnosed with a type of blood cancer called B-cell non-Hodgkin lymphoma (B-NHL), confirmed by a lab test
- You have already received at least 2 different types of treatment for your cancer
- Your last treatment either stopped working, your cancer came back after it, or you could not tolerate it — and you currently need further treatment
- Your cancer can be measured on a scan (there are visible areas of disease that can be tracked)
- Your doctors expect you to live for more than 12 weeks
- You are in relatively good general health and able to carry out daily activities with little or no limitation (confirm with trial site)
- If you can become pregnant, you have a negative pregnancy test before starting and agree to use reliable contraception and not donate eggs for 1 year after treatment; if you are a man who could father a child, you agree to use reliable contraception and not donate sperm for 1 year after treatment
Who may not be able to join:
- You are pregnant or breastfeeding
- You have HIV, syphilis, active hepatitis B, or active hepatitis C
- You currently have any uncontrolled active infection, including active tuberculosis
- You still have significant side effects from a previous cancer treatment that have not cleared up (with some exceptions, such as hair loss)
- You have received cancer treatment — such as chemotherapy, targeted therapy, radiotherapy, or similar — within the 14 days before joining the study (with a possible exception for limited radiotherapy — confirm with trial site)
- You have been taking high-dose steroid tablets (such as prednisone above a certain daily dose) within the 7 days before joining the study (topical steroids applied to the skin are allowed)
- You have received any vaccine — including flu shots or COVID vaccines — within 4 weeks before joining the study
- You have a known allergy or intolerance to certain medications used in this study, or you have previously had a severe allergic reaction such as anaphylactic shock
- You have had any heart condition in the 6 months before screening
- Your blood oxygen level is below 92%
- You have another cancer that is still being treated or has not been fully cleared within the past 2 years
- You have had major surgery within 2 weeks before joining, or major surgery is planned during the study or within 4 weeks of receiving the study treatment (minor procedures like cataract surgery may be an exception)
- The study doctor feels you are unable or unwilling to follow the study requirements for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Aibin Liang MD,Ph.D., Shanghai Tongji Hospital, Tongji University School of Medicine
Phone: +86 21 6611 1019
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Adverse Events (AE) after CT1190B infusion; MTD and/or dose range
Can't join this trial?
Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.